
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a promising biotechnology company with a unique platform for delivering oligonucleotide therapeutics to a wide range of target tissues, including the central nervous system. While the recent clinical data from their PGN-EDODM1 drug is still early and somewhat complicated to interpret, their ability to improve tissue concentrations and show improvements in clinical function is encouraging. There may be some concerns about the safety profile, but overall, PepGen is well-positioned to advance in the biotech market and has the potential for significant growth as they continue to pursue their pipeline of drugs for severe neuromuscular diseases.
Bears say
PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform for improving the uptake and activity of conjugated oligonucleotide therapeutics. However, the company's recent FREEDOM-2 study results for its lead product PGN-EDODM1 are difficult to interpret and reflect early-stage data. With the upcoming 10mg/kg data from FREEDOM-2 expected to establish a "go/no-go" decision for the program and the company's shares trading below their target, a negative outlook is warranted until further clarity is provided.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares